Julie Baugher, MD
Internal Medicine · Southern Pines, NCNPI 1245218999
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,075 of the $80,774 with a category attached, or 68.2%. Lilly USA, LLC accounts for 95.2% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $48,032, more than ten times the $376 reported in 2019. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $213.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$77K
- Novo Nordisk$1K
- Johnson & Johnson$577
- AbbVie$344
- Pfizer$203
- Abbott$180
- plus $1K from 18 others
What the payments were for
- Consulting fees$8,05010%
- Speaking & faculty fees$55,07568%
- Travel & lodging$9,56212%
- Food & beverage$8,06010%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 173 | $76,880 |
| Novo Nordisk | 82 | $1,346 |
| Johnson & Johnson | 14 | $577 |
| AbbVie | 18 | $344 |
| Pfizer | 13 | $203 |
| Abbott | 8 | $180 |
| AstraZeneca | 13 | $180 |
| Daiichi Sankyo Inc. | 6 | $149 |
| Exact Sciences | 8 | $147 |
| Amgen | 10 | $146 |
| Boehringer Ingelheim | 7 | $134 |
| Bayer | 6 | $105 |
| Mylan Specialty L.p. | 5 | $98 |
| Astellas Pharma US Inc | 2 | $43 |
| Shield Therapeutics Inc | 2 | $42 |
| Rhythm Pharmaceuticals, Inc. | 2 | $38 |
| Hologic Sales And Service, LLC | 2 | $33 |
| Seqirus USA Inc | 1 | $25 |
| Valeritas, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Merck | 1 | $16 |
| Medtronic | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,774 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $209,788 |
| MounjaroTirzepatide | 139 | $150,939 |
| EliquisApixaban | 130 | $119,540 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $101,445 |
| JardianceEmpagliflozin | 38 | $45,266 |
| MyrbetriqMirabegron | 27 | $29,142 |
| XareltoRivaroxaban | 21 | $22,661 |
| RybelsusSemaglutide | 21 | $22,322 |
| WegovySemaglutide | 12 | $15,726 |
| FarxigaDapagliflozin Propanediol | 19 | $12,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,815 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,903 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $6,826 |
| Atorvastatin Calcium | 552 | $6,753 |
| PremarinEstrogens, Conjugated | 13 | $6,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy, Levemir | $1,346 | $250,387188 claims |
| Lilly USA, LLCMounjaro | $76,880 | $150,939139 claims |
| PfizerEliquis, Premarin | $203 | $126,287143 claims |
| Boehringer IngelheimJardiance | $134 | $45,26638 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $29,14227 claims |
| Johnson & JohnsonXarelto | $577 | $22,66121 claims |
| AstraZenecaFarxiga, Brilinta | $180 | $19,08232 claims |
| AbbVieSynthroid | $344 | $4,34851 claims |
| Sanofi-aventis U.S. LLCLantus | $12 | $1,57812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Southern Pines
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.